Indication
Indolent B-cell Lymphoma
1 clinical trial
3 products
Clinical trial
A Phase 2 Study of Acalabrutinib in Combination With Lisocabtagene Maraleucel in Relapsed/Refractory Aggressive B-cell LymphomasStatus: Recruiting, Estimated PCD: 2025-03-01
Product
ACALABRUTINIBProduct
Lisocabtagene maraleucelProduct
Lymphodepleting chemotherapy